David Rosa Biography and Net Worth

Mr. Rosa is an entrepreneur with three decades of experience in the medical device industry spanning a variety of technologies and products. In addition to CEO roles with early-stage medical device companies, Mr. Rosa’s background also includes senior roles with C.R. Bard Inc., Boston Scientific Inc., and St. Jude Medical, where his responsibilities included marketing, product development and business development. He has been named as an inventor on multiple medical device patents, serves on seven corporate boards, and has raised $200M in the capital markets. Mr. Rosa holds an MBA from Duquesne University and a BS in Commerce and Engineering from Drexel University.

What is David A. Rosa's net worth?: The estimated net worth of David A. Rosa is at least $218.71 thousand as of April 4th, 2025. Rosa owns 193,548 shares of NeuroOne Medical Technologies stock worth more than $218,709 as of October 6th. This net worth evaluation does not reflect any other investments that Rosa may own. Learn More about David A. Rosa's net worth.
How do I contact David A. Rosa?: The corporate mailing address for Rosa and other NeuroOne Medical Technologies executives is 7599 Anagram DR, Eden Prairie, MN, 55344. NeuroOne Medical Technologies can also be reached via phone at (952) 426-1383 and via email at [email protected]. Learn More on David A. Rosa's contact information.
Has David A. Rosa been buying or selling shares of NeuroOne Medical Technologies?: David A. Rosa has not been actively trading shares of NeuroOne Medical Technologies within the last three months. Most recently, on Friday, April 4th, David A. Rosa bought 16,666 shares of NeuroOne Medical Technologies stock. The stock was acquired at an average cost of $3.00 per share, with a total value of $49,998.00. Following the completion of the transaction, the chief executive officer now directly owns 193,548 shares of the company's stock, valued at $580,644. Learn More on David A. Rosa's trading history.
Who are NeuroOne Medical Technologies' active insiders?: NeuroOne Medical Technologies' insider roster includes Mark Christianson (Director), and David Rosa (CEO). Learn More on NeuroOne Medical Technologies' active insiders.
Are insiders buying or selling shares of NeuroOne Medical Technologies?: During the last year, NeuroOne Medical Technologies insiders bought shares 2 times. They purchased a total of 199,999 shares worth more than $736,996.65. During the last year, insiders at the sold shares 5 times. They sold a total of 12,438 shares worth more than $43,502.40. The most recent insider tranaction occured on August, 27th when insider David J Wambeke bought 33,333 shares worth more than $66,999.33. Insiders at NeuroOne Medical Technologies own 11.8% of the company. Learn More about insider trades at NeuroOne Medical Technologies.
Information on this page was last updated on 8/27/2026.

David A. Rosa Insider Trading History at NeuroOne Medical Technologies

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
4/4/2025	Buy	16,666	$3.00	$49,998.00	193,548

David A. Rosa Buying and Selling Activity at NeuroOne Medical Technologies

NeuroOne Medical Technologies Company Overview

NeuroOne Medical Technologies Corporation, a developmental stage company, provides solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other related neurological disorders. It also fucuses on applications for other areas, such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator. The company was incorporated in 2009 and is based in Eden Prairie, Minnesota.

Today's Range

Now: $1.13

$1.10

$1.17

50 Day Range

MA: $1.61

$0.99

$2.18

2 Week Range

Now: $1.13

$0.96

$6.96

Volume

109,037 shs

Average Volume

138,850 shs

Market Capitalization

$10.29 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.77